Table 1 Comparison of presenting clinical and laboratory findings according to the applied therapy of older patients with acute promyelocytic leukemia.

From: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study

Characteristics

CTX/ATRA

n = 259

CTX/ATRA/ ATO

n = 148

ATO/ATRA

n = 26

P value

Age, years

 Median

73.4

73.2

76

0.07

 Range

70–88.7

70–89

71–87

Gender, no. (%)

 Male

123 (47)

80 (54)

18 (69)

0.07

 Female

136 (53)

68 (46)

8 (31)

WBC, ×109/l

 Median

2.1

1.3

0.8

<0.001

 Range

0.1–764

0.2–136

0.2–3.6

 Missing

4

0

0

Hemoglobin, g/dl

 Median

9.2

9.7

9.2

0.20

 Range

4.0–15.2

4.6–14.3

6.0–14.0

 Missing

14

2

17

Platelet count, ×109/l

 Median

34

41

43

0.08

 Range

3–213

4–261

11–195

 Missing

8

3

2

Percentage of PB blastsa

 Median

61

6

1

<0.001

 Range

0–100

0–99

0–67

 Missing

53

15

7

Percentage of BM blastsa

 Median

80

74

50

0.005

 Range

13–100

12–98

3–90

 Missing

42

0

11

 High-riskb

72 (28)

18 (12)

0

<0.001

 Missing

4

0

0

  1. Percentages may not add to 100 because of rounding.
  2. ATO arsenic trioxide, ATRA all-trans retinoic acid, BM bone marrow, CTX chemotherapy, PB peripheral blood, WBC white blood cell counts.
  3. aBlast cells included malignant promyelocytes.
  4. bHigh risk: WBC > 10 × 109/l.
Back to article page